Understanding Fluoroquinolone Resistance in Streptococcus pneumoniae
Author Information
Author(s): Lim Sue, Bast Darrin, McGeer Allison, de Azavedo Joyce, Low Donald E.
Primary Institution: Toronto Medical Laboratories/Mount Sinai Hospital
Hypothesis
Can levofloxacin breakpoints effectively identify Streptococcus pneumoniae isolates with resistance mechanisms?
Conclusion
Levofloxacin susceptibility testing using current clinical breakpoints fails to identify most S. pneumoniae isolates with first-step parC mutations.
Supporting Evidence
- 59% of isolates with a levofloxacin MIC of 2 μg/mL had a first-step mutation in parC.
- Current NCCLS breakpoints do not effectively detect emerging fluoroquinolone resistance.
- First-step mutations in parC are associated with decreased susceptibility to fluoroquinolones.
Takeaway
This study found that many bacteria thought to be treatable with levofloxacin actually have mutations that make them resistant, even if tests say they're okay.
Methodology
The study examined 115 S. pneumoniae isolates for parC mutations and performed susceptibility testing using NCCLS guidelines.
Limitations
The study may not account for all resistance mechanisms and relies on specific breakpoints that may not be accurate.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website